The Stable Nitroxide Tempol Facilitates Salivary Gland Protection during Head and Neck Irradiation in a Mouse Model

Joseph M Vitolo, Ana P. Cotrim, Anastasia L. Sowers, Angelo Russo, Robert B. Wellner, Stanley R. Pillemer, James B. Mitchell, Bruce J. Baum

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Purpose: Radiotherapy is commonly used to treat a majority of patients with head and neck cancers. The long-term radiation-induced reduction of saliva output significantly contributes to the posttreatment morbidity experienced by these patients. The purpose of this study was to test the ability of the stable-free radical Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), an established radioprotector, to prevent radiation-induced salivary hypofunction in mice. Experimental Design: The heads of C3H mice were exposed to a range of single radiation doses with or without an i.p. injection of 275 mg/kg Tempol 10 min before treatment. Salivary gland output was assessed 8 weeks postirradiation. Results: Radiation caused a dose-dependent reduction in salivary flow in this model. Tempol treatment alone significantly reduced radiation-induced salivary hypofunction. The combination of Tempol with mouth/nose shielding showed essentially complete radiation protection at 15 Gy and ∼75% protection at 17.5 Gy. Conclusions: This study demonstrates for the first time that significant radioprotection of the salivary glands is possible with Tempol in C3H mice.

Original languageEnglish (US)
Pages (from-to)1807-1812
Number of pages6
JournalClinical Cancer Research
Volume10
Issue number5
DOIs
StatePublished - Mar 1 2004
Externally publishedYes

Fingerprint

Salivary Glands
Neck
Head
Radiation
Inbred C3H Mouse
Radiation Protection
Head and Neck Neoplasms
Nose
Saliva
Free Radicals
Mouth
tempol
Research Design
Radiotherapy
Morbidity
Injections
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The Stable Nitroxide Tempol Facilitates Salivary Gland Protection during Head and Neck Irradiation in a Mouse Model. / Vitolo, Joseph M; Cotrim, Ana P.; Sowers, Anastasia L.; Russo, Angelo; Wellner, Robert B.; Pillemer, Stanley R.; Mitchell, James B.; Baum, Bruce J.

In: Clinical Cancer Research, Vol. 10, No. 5, 01.03.2004, p. 1807-1812.

Research output: Contribution to journalArticle

Vitolo, JM, Cotrim, AP, Sowers, AL, Russo, A, Wellner, RB, Pillemer, SR, Mitchell, JB & Baum, BJ 2004, 'The Stable Nitroxide Tempol Facilitates Salivary Gland Protection during Head and Neck Irradiation in a Mouse Model', Clinical Cancer Research, vol. 10, no. 5, pp. 1807-1812. https://doi.org/10.1158/1078-0432.CCR-03-0194
Vitolo, Joseph M ; Cotrim, Ana P. ; Sowers, Anastasia L. ; Russo, Angelo ; Wellner, Robert B. ; Pillemer, Stanley R. ; Mitchell, James B. ; Baum, Bruce J. / The Stable Nitroxide Tempol Facilitates Salivary Gland Protection during Head and Neck Irradiation in a Mouse Model. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 5. pp. 1807-1812.
@article{8c5fc6518698421b88307893189e2646,
title = "The Stable Nitroxide Tempol Facilitates Salivary Gland Protection during Head and Neck Irradiation in a Mouse Model",
abstract = "Purpose: Radiotherapy is commonly used to treat a majority of patients with head and neck cancers. The long-term radiation-induced reduction of saliva output significantly contributes to the posttreatment morbidity experienced by these patients. The purpose of this study was to test the ability of the stable-free radical Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), an established radioprotector, to prevent radiation-induced salivary hypofunction in mice. Experimental Design: The heads of C3H mice were exposed to a range of single radiation doses with or without an i.p. injection of 275 mg/kg Tempol 10 min before treatment. Salivary gland output was assessed 8 weeks postirradiation. Results: Radiation caused a dose-dependent reduction in salivary flow in this model. Tempol treatment alone significantly reduced radiation-induced salivary hypofunction. The combination of Tempol with mouth/nose shielding showed essentially complete radiation protection at 15 Gy and ∼75{\%} protection at 17.5 Gy. Conclusions: This study demonstrates for the first time that significant radioprotection of the salivary glands is possible with Tempol in C3H mice.",
author = "Vitolo, {Joseph M} and Cotrim, {Ana P.} and Sowers, {Anastasia L.} and Angelo Russo and Wellner, {Robert B.} and Pillemer, {Stanley R.} and Mitchell, {James B.} and Baum, {Bruce J.}",
year = "2004",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-03-0194",
language = "English (US)",
volume = "10",
pages = "1807--1812",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - The Stable Nitroxide Tempol Facilitates Salivary Gland Protection during Head and Neck Irradiation in a Mouse Model

AU - Vitolo, Joseph M

AU - Cotrim, Ana P.

AU - Sowers, Anastasia L.

AU - Russo, Angelo

AU - Wellner, Robert B.

AU - Pillemer, Stanley R.

AU - Mitchell, James B.

AU - Baum, Bruce J.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Purpose: Radiotherapy is commonly used to treat a majority of patients with head and neck cancers. The long-term radiation-induced reduction of saliva output significantly contributes to the posttreatment morbidity experienced by these patients. The purpose of this study was to test the ability of the stable-free radical Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), an established radioprotector, to prevent radiation-induced salivary hypofunction in mice. Experimental Design: The heads of C3H mice were exposed to a range of single radiation doses with or without an i.p. injection of 275 mg/kg Tempol 10 min before treatment. Salivary gland output was assessed 8 weeks postirradiation. Results: Radiation caused a dose-dependent reduction in salivary flow in this model. Tempol treatment alone significantly reduced radiation-induced salivary hypofunction. The combination of Tempol with mouth/nose shielding showed essentially complete radiation protection at 15 Gy and ∼75% protection at 17.5 Gy. Conclusions: This study demonstrates for the first time that significant radioprotection of the salivary glands is possible with Tempol in C3H mice.

AB - Purpose: Radiotherapy is commonly used to treat a majority of patients with head and neck cancers. The long-term radiation-induced reduction of saliva output significantly contributes to the posttreatment morbidity experienced by these patients. The purpose of this study was to test the ability of the stable-free radical Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), an established radioprotector, to prevent radiation-induced salivary hypofunction in mice. Experimental Design: The heads of C3H mice were exposed to a range of single radiation doses with or without an i.p. injection of 275 mg/kg Tempol 10 min before treatment. Salivary gland output was assessed 8 weeks postirradiation. Results: Radiation caused a dose-dependent reduction in salivary flow in this model. Tempol treatment alone significantly reduced radiation-induced salivary hypofunction. The combination of Tempol with mouth/nose shielding showed essentially complete radiation protection at 15 Gy and ∼75% protection at 17.5 Gy. Conclusions: This study demonstrates for the first time that significant radioprotection of the salivary glands is possible with Tempol in C3H mice.

UR - http://www.scopus.com/inward/record.url?scp=1842428592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842428592&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-03-0194

DO - 10.1158/1078-0432.CCR-03-0194

M3 - Article

C2 - 15014035

AN - SCOPUS:1842428592

VL - 10

SP - 1807

EP - 1812

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -